Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
arcticnovartis
Fri, 07/17/2026 – 01:19
Read more about Novartis Fabhalta® (iptaco…
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
arcticnovartis
Mon, 07/06/2026 – 07:03
Read more about Novartis agrees to acquire …
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
arcticnovartis
Thu, 07/02/2026 – 07:04
Read more about Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
…
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
arcticnovartis
Fri, 06/12/2026 – 11:49
Read more about Novartis RemIND data at EAACI show Rhapsido® potential as first targete…
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
arcticnovartis
Thu, 06/11/2026 – 07:04
Read more about Novartis delpacibart braxlosiran (del-brax) Phase…
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
arcticnovartis
Mon, 06/08/2026 – 09:04
Read more about Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Cong…
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
arcticnovartis
Thu, 06/04/2026 – 12:19
Read more about Novartis IgAN data in The Lancet show clinically meaningful slowing…
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
arcticnovartis
Wed, 06/03/2026 – 17:34
Read more about Novartis Cosentyx® PMR data in New England Journal of Medicine sh…
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
arcticnovartis
Mon, 06/01/2026 – 13:19
Read more about Scemblix® continued to show superior efficacy and favorable safet…
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
arcticnovartis
Mon, 06/01/2026 – 07:19
Read more about Novartis data at EULAR 2026 demonstrates momentum for broad immunology po…